Key statistics
On Monday, Annovis Bio Inc (07X:FRA) closed at 7.51, 69.91% above the 52 week low of 4.42 set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.51 |
---|---|
High | 7.51 |
Low | 7.51 |
Bid | 7.15 |
Offer | 7.29 |
Previous close | 7.62 |
Average volume | 185.29 |
---|---|
Shares outstanding | 13.05m |
Free float | 10.24m |
P/E (TTM) | -- |
Market cap | 110.57m USD |
EPS (TTM) | -4.42 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 07:16 BST.
More ▼
Announcements
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
- Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
- Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
- Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
- Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
More ▼